Therapie des Graft-versus-Host-Erkrankung (GVHD) - Globale Marktgröße, Marktanteil und Trends Analysebericht - Branchenübersicht und Prognose bis 2032

Global Graft Versus Host Disease Gvhd Treatment Market

Marktgröße in Milliarden USD

CAGR : 4.70 %

USD 4.07 Billion USD 5.81 Billion 2024 2032

Prognosezeitraum	2025 –2032
Marktgröße (Basisjahr)	USD 4.07 Billion
Marktgröße (Prognosejahr)	USD 5.81 Billion
CAGR	4.70 %
Wichtige Marktteilnehmer	Bristol-Myers Squibb Company AbbVie Inc. Novartis AG Mallinckrodt Incyte

Global Graft-Versus-Host Disease (GvHD) Treatment Market, By Treatment (Medication and Therapy), Type (Chronic GvHD, Acute GvHD, and Prophylactic), Gender (Female and Male), Age (Adults and Pediatric), Method of Administration (Oral, Intravenous, Topical, and Others), End User (Hospitals, Transplant Centers, Institutes and Specialty Centers), Distribution Channel (Direct Tender, Retail Sales and Others - Industry Trends and Forecast to 2031.

Graft-Versus-Host Disease (GvHD) Treatment Market Analysis and Insights

According to an article published by National Institutes of Health in August 2023, as per the study conducted across 24 HCT centers in North America, Europe, and Asia investigated the natural progression of GvHD, the total incidence of acute GvHD requiring treatment was 40.9%, 35.2% for classic acute GvHD and 5.7% for late acute GvHD. Among patients with classic and late acute GvHD, 77.8% (1245 out of 1601) and 75.4% (193 out of 256), respectively, received systemic GvHD treatment. according to an article published by National Library of Medicine, acute graft-versus-host disease (GvHD) can develop in approximately half of patients undergoing hematopoietic stem cell transplantation (HCT) from a human leukocyte antigen (HLA)-matched sibling.

Data Bridge Market Research analyses that the global Graft-Versus-Host Disease (GvHD) treatment market is expected to reach USD 5.50 billion by 2031 from USD 3.94 billion in 2023, growing at a CAGR of 4.4% in in the forecast period of 2024 to 2031.

Report Metric	Details
Forecast Period	2024 to 2031
Base Year	2023
Historic Years	2022 (Customizable to 2016–2021)
Quantitative Units	Revenue in USD Billion
Segments Covered	Treatment (Medication and Therapy), Type (Chronic GvHD, Acute GvHD, and Prophylactic), Gender (Female and Male), Age (Adults and Pediatric), Method of Administration (Oral, Intravenous, Topical, and Others), End User (Hospitals, Transplant Centers, Institutes and Specialty Centers), Distribution Channel (Direct Tender, Retail Sales and Others)
Countries Covered	U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Belgium, Russia, Switzerland, Denmark, Rest of Europe, China, Japan, Australia, South Korea, India, Malaysia, Singapore, Philippines, Indonesia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Kuwait, Bahrain, and Rest of Middle East and Africa
Market Players Covered	Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, Janssen Global Services, LLC, MALLINCKRODT PLC, Incyte., Sanofi, Alkem Laboratories Ltd., and Astellas Pharma Inc., among others

Market Definition

Die Graft-versus-Host-Krankheit (GvHD) ist eine Erkrankung, die nach einer Stammzellen- oder Knochenmarkstransplantation auftreten kann, bei der die frisch transplantierten Spenderzellen den Körper des Transplantatempfängers angreifen. Diese Immunreaktion kann eine Reihe von Symptomen und Komplikationen verursachen, die von leicht bis schwer reichen. GvHD ist ein erhebliches Problem in der Transplantationsmedizin und erfordert eine sorgfältige Behandlung.

Die Behandlung der Graft-versus-Host-Krankheit (GvHD) umfasst die verschiedenen medizinischen Eingriffe zur Behandlung und Linderung der Symptome der GvHD. Diese Behandlungen zielen darauf ab, die Immunreaktion der Spenderzellen gegen die Gewebe und Organe des Empfängers zu unterdrücken. Zu den üblichen Behandlungen für GvHD gehören immunsuppressive Medikamente wie Kortikosteroide sowie andere Medikamente, die auf bestimmte Aspekte der Immunreaktion abzielen. In schweren Fällen können intensivere Therapien wie Photopherese oder andere immunmodulierende Therapien eingesetzt werden. Die Wahl der Behandlung hängt vom Schweregrad der GvHD und anderen Faktoren ab, die für den einzelnen Patienten spezifisch sind.

Globale Marktdynamik für die Behandlung der Graft-versus-Host-Krankheit (GvHD)

In diesem Abschnitt geht es um das Verständnis der Markttreiber, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:

Treiber

Zunehmende Häufigkeit von hämatopoetischen Stammzelltransplantationen (HSCT)

Die zunehmende Häufigkeit von hämatopoetischen Stammzelltransplantationen (HSCT) ist ein wesentlicher Treiber für die Nachfrage nach Behandlungen der Graft-versus-Host-Krankheit (GvHD). Dieser Trend wird hauptsächlich durch die zunehmende Verbreitung von Blutkrebsarten wie Leukämie, Lymphom und Myelom vorangetrieben, die häufig eine HSCT als Behandlungsoption erfordern. Darüber hinaus erfordern auch andere hämatologische Erkrankungen wie aplastische Anämie und bestimmte genetische Erkrankungen eine HSCT zur Krankheitsbehandlung.

Da die Zahl der Patienten, die sich einer HSCT unterziehen, weiter steigt, steigt auch der Bedarf an einer wirksamen GvHD-Behandlung. GvHD ist eine häufige Komplikation der HSCT. Sie tritt auf, wenn die transplantierten Spenderzellen das Gewebe des Empfängers angreifen, was zu potenziell schweren und lebensbedrohlichen Symptomen führt. Daher führt die zunehmende Inzidenz der HSCT direkt zu einem höheren Bedarf an GvHD-Behandlungen, um die Auswirkungen dieser Komplikation zu kontrollieren und zu mildern.

Zurückhaltung

Hohe Kosten für Medikamente und unterstützende Pflege

Die hohen Kosten für die Behandlung der Graft-versus-Host-Krankheit (GvHD) stellen eine Einschränkung dar, die über die bloße Erschwinglichkeit von Medikamenten hinausgeht. Sie umfassen die Kosten für eine umfassende Behandlung, einschließlich Medikamente, Krankenhausaufenthalte, ambulante Besuche, diagnostische Tests und unterstützende Therapien. In Entwicklungsregionen mit begrenzten Gesundheitsressourcen und finanziellen Einschränkungen können diese Kosten besonders belastend sein und oft zu einer verzögerten oder unzureichenden Behandlung führen.

Calcineurin-Inhibitoren wie Tacrolimus und Cyclosporin sind wichtige Bestandteile der GvHD-Behandlung, aber ihre hohen Kosten können die Gesundheitsbudgets belasten. Antimetaboliten wie Methotrexat und Mycophenolatmofetil, Immunsuppressiva wie Ruxolitinib, Belumosudil und Ibrutinib sowie Kortikosteroide wie Methylprednisolon und Prednisolon sind ebenfalls unverzichtbar, stellen jedoch eine übermäßige finanzielle Belastung für die Patienten dar.

Gelegenheit

Markterweiterung durch strategische Initiativen und Partnerschaften

Die Markterweiterung durch strategische Zusammenarbeit kann für Unternehmen, die auf dem Markt für die Behandlung von GvHD (Graft-versus-Host Disease) tätig sind, ein äußerst effektiver Ansatz sein. Da die Nachfrage nach innovativen Behandlungen und umfassenden Pflegelösungen für GvHD weiter steigt, können Unternehmen strategische Partnerschaften und Kooperationen nutzen, um ihre Marktpräsenz auszubauen und ein vielfältiges Produktportfolio anzubieten, das auf die sich entwickelnden Bedürfnisse der Patienten zugeschnitten ist. Durch die Zusammenarbeit mit Forschungseinrichtungen, akademischen Zentren und Biotechnologieunternehmen können Akteure auf dem GvHD-Markt auf Spitzentechnologien, neuartige therapeutische Ansätze und wissenschaftliche Expertise zugreifen, um ihre Produktentwicklung voranzutreiben. Diese Kooperationen ermöglichen es Unternehmen, die Entdeckung und Entwicklung vielversprechender GvHD-Therapien zu beschleunigen, darunter personalisierte Zelltherapien, gezielte biologische Wirkstoffe und unterstützende Pflegemaßnahmen. Darüber hinaus erleichtern strategische Allianzen mit wichtigen Meinungsführern und Patientenvertretungen den Marktzugang und fördern die Einführung neuer Behandlungen, indem sie Vertrauen, Glaubwürdigkeit und Patientenengagement fördern.

Darüber hinaus ermöglicht die Markterweiterung durch strategische Initiativen den GvHD-Marktteilnehmern, ihr Produktportfolio zu diversifizieren und einen größeren Anteil des GvHD-Marktes zu erobern. Indem sie ihr Fachwissen und ihre Ressourcen nutzen, um ergänzende Produkte und Dienstleistungen zu entwickeln, können Unternehmen umfassende Pflegelösungen anbieten, die den vielfältigen Bedürfnissen von GvHD-Patienten in verschiedenen Stadien des Krankheitsverlaufs gerecht werden.

Herausforderung

Strenge Vorschriften für die Therapie der GvHD

Strenge Regulierungen stellen für den GvHD-Markt in Zukunft eine große Herausforderung dar. Während sich das Feld mit der Entwicklung neuer Therapien und Behandlungsmethoden weiterentwickelt, legen die Aufsichtsbehörden strenge Standards für Sicherheit, Wirksamkeit und Qualitätskontrolle fest. Die Erfüllung dieser regulatorischen Anforderungen erfordert erhebliche Investitionen in die präklinische und klinische Entwicklung sowie umfangreiche Dokumentation und Dateneinreichung zur behördlichen Genehmigung. Darüber hinaus erschweren die Komplexität der GvHD, ihre heterogene Präsentation und das Fehlen standardisierter Diagnosekriterien die behördlichen Bewertungs- und Genehmigungsprozesse zusätzlich. Aufsichtsbehörden verlangen oft solide Daten aus klinischen Studien, die nicht nur die Wirksamkeit neuer Therapien, sondern auch ihre vergleichbare Wirksamkeit gegenüber bestehenden Behandlungen belegen. Dies erfordert groß angelegte, gut konzipierte klinische Studien mit langen Nachbeobachtungszeiträumen, was zu längeren Zeitplänen und höheren Kosten für die Produktentwicklung führt.

Jüngste Entwicklungen

Im März 2024 gab Johnson & Johnson den erfolgreichen Abschluss der Übernahme von Ambrx Biopharma, Inc. bekannt. Dieses biopharmazeutische Unternehmen in der klinischen Phase verfügt über eine proprietäre synthetische Biotechnologieplattform, die für die Entwicklung und den Entwurf von Antikörper-Wirkstoff-Konjugaten (ADCs) der nächsten Generation verwendet wird. Diese Übernahme bietet Johnson & Johnson eine einzigartige Gelegenheit, gezielte Onkologietherapien zu entwickeln und zu vermarkten.
Im Februar 2024 haben AbbVie Inc. und Tentarix Biotherapeutics eine Partnerschaft zur gemeinsamen Erforschung und Entwicklung bedingt aktiver, multispezifischer Biologika in den Bereichen Onkologie und Immunologie angekündigt. Diese Zusammenarbeit wird die umfassende Erfahrung von AbbVie in diesen Bereichen zusammen mit der proprietären Tentacles™-Plattform von Tentarix nutzen. Im April 2023 gründeten Medtronic und DaVita Inc. gemeinsam Mozarc Medical, ein unabhängiges Unternehmen, das sich der Verbesserung der Nierengesundheit und der Weiterentwicklung patientenzentrierter Technologielösungen widmet.
Im Februar 2024 hat die Novartis AG die Übernahme der MorphoSys AG vereinbart, eines deutschen biopharmazeutischen Unternehmens, das sich auf innovative Krebsmedikamente konzentriert. Diese Übernahme, die den üblichen Abschlussbedingungen und behördlichen Genehmigungen unterliegt, stärkt die Onkologie-Pipeline von Novartis und erweitert ihre globale Präsenz in der Hämatologie
Im Mai 2022 gab Bristol-Myers Squibb Company die Zulassung von Opdivo plus Yervoy als Erstlinienbehandlung für erwachsene Patienten mit GvHD durch das japanische Ministerium für Gesundheit, Arbeit und Soziales bekannt. Dies könnte dem Unternehmen helfen, sein Produktportfolio zu stärken
Im Januar 2020 gab Astellas Pharma Inc. bekannt, dass es eine Vereinbarung mit Adaptimmune zur Entwicklung von aus Stammzellen gewonnenen allogenen CAR-T- und TCR-T-Zelltherapien zur Behandlung von Krebs geschlossen hat. Dies wird dem Unternehmen helfen, den Markt in den kommenden Jahren weiter zu erobern.

Globaler Marktumfang zur Behandlung der Graft-versus-Host-Krankheit (GvHD)

Der globale Markt für Behandlungen der Graft-Versus-Host-Krankheit (GvHD) ist in sieben wichtige Segmente unterteilt, basierend auf Behandlung, Art, Geschlecht, Alter, Verabreichungsmethode, Endbenutzer und Vertriebskanal. Das Wachstum zwischen den Segmenten hilft Ihnen bei der Analyse von Nischenwachstumsbereichen und Strategien zur Marktbearbeitung und zur Bestimmung Ihrer wichtigsten Anwendungsbereiche und der Unterschiede in Ihren Zielmärkten.

Behandlung

Medikamente
Therapie

Auf der Grundlage der Behandlung wird der Markt in Medikamente und Therapien segmentiert.

Typ

Chronische GvHD
Akute GvHD
Prophylaktisch

Auf der Grundlage des Typs ist der Markt in chronische GvHD, akute GvHD und prophylaktische Behandlung segmentiert.

Geschlecht

Weiblich
Männlich

Auf der Grundlage des Geschlechts ist der Markt in weiblich und männlich segmentiert.

Alter

Erwachsene
Pädiatrie

Auf der Grundlage des Alters ist der Markt in Erwachsene und Kinder segmentiert.

Art der Anwendung

Oral
Intravenös
Aktuell
Sonstiges

Auf der Grundlage der Verabreichungsmethode ist der Markt in oral, intravenös, topisch und andere unterteilt.

Endbenutzer

Krankenhäuser
Transplantationszentren
Institute
Spezialzentren

Auf der Grundlage des Endbenutzers ist der Markt in Krankenhäuser, Transplantationszentren, Institute und Fachzentren segmentiert.

Vertriebskanal

Direkte Ausschreibung
Einzelhandelsumsätze
Sonstiges

Auf der Grundlage des Vertriebskanals wird der Markt in Direktausschreibungen, Einzelhandelsverkäufe und Sonstiges segmentiert.

Globale Marktanalyse/Einblicke zur Behandlung der Graft-versus-Host-Krankheit (GvHD)

Der globale Markt für Behandlungen der Graft-Versus-Host-Krankheit (GvHD) ist basierend auf Behandlung, Typ, Geschlecht, Alter, Verabreichungsmethode, Endbenutzer und Vertriebskanal in sieben wichtige Segmente unterteilt.

Die in diesem Marktbericht abgedeckten Länder sind die USA, Kanada, Mexiko, Deutschland, Frankreich, Italien, Großbritannien, Spanien, Belgien, Russland, die Schweiz, Dänemark, das übrige Europa, China, Japan, Australien, Südkorea, Indien, Malaysia, Singapur, die Philippinen, Indonesien, der restliche asiatisch-pazifische Raum, Brasilien, Argentinien, das übrige Südamerika, Südafrika, Saudi-Arabien, die Vereinigten Arabischen Emirate, Kuwait, Bahrain sowie der restliche Nahe Osten und Afrika.

Die Region Nordamerika wird voraussichtlich den Markt dominieren, aufgrund ihrer modernen Gesundheitsinfrastruktur, hohen Raten an hämatopoetischen Zelltransplantationen, soliden Investitionen in Forschung und Entwicklung, einem unterstützenden regulatorischen Umfeld, erheblichen Gesundheitsausgaben und einem größeren Bewusstsein für die Krankheit. Diese Faktoren tragen zur führenden Position der Region bei der Entwicklung und Einführung neuer GvHD-Behandlungen bei. Die USA werden voraussichtlich in Nordamerika dominieren, aufgrund der zunehmenden Häufigkeit hämatopoetischer Stammzelltransplantationen (HSCT). Japan wird voraussichtlich in der Region Asien-Pazifik dominieren, aufgrund moderner Medizintechnik, erheblicher Investitionen in Forschung und Entwicklung im Gesundheitswesen, einer hohen Rate an hämatopoetischen Zelltransplantationen, starker staatlicher Unterstützung und regulatorischer Effizienz bei der Zulassung neuer Behandlungen und einem erhöhten öffentlichen Bewusstsein und einer erhöhten Aufklärung über GvHD. Deutschland wird voraussichtlich in der Region Europa dominieren, aufgrund seines Einsatzes moderner Technologien, seiner robusten Gesundheitsinfrastruktur und seines reifen Marktes.

Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Regulierung auf dem Inlandsmarkt, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neuverkäufe, Ersatzverkäufe, Länderdemografie, Regulierungsgesetze und Import-/Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit globaler Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.

Wettbewerbsumfeld und globale Behandlung der Graft-Versus-Host-Krankheit (GvHD) Marktanteilsanalyse

Das Wettbewerbsumfeld auf dem globalen Markt für die Behandlung der Graft-versus-Host-Krankheit (GvHD) liefert Einzelheiten zu den Wettbewerbern. Zu den enthaltenen Details gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Produktionsstandorte und -einrichtungen, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktzulassungen, Produktbreite und -umfang, Anwendungsdominanz und Produkttyp-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens auf den Markt.

Zu den wichtigsten Marktteilnehmern auf dem Markt zählen unter anderem Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, Janssen Global Services, LLC, MALLINCKRODT PLC, Incyte., Sanofi, Alkem Laboratories Ltd. und Astellas Pharma Inc.

SKU-63917

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Klicken Sie auf das Bild, um es zu vergrößern

Interaktives Datenanalyse-Dashboard
Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
Zugriff für Research-Analysten für Anpassungen und Abfragen
Konkurrenzanalyse mit interaktivem Dashboard
Aktuelle Nachrichten, Updates und Trendanalyse
Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung

Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS FIVE FORCES ANALYSIS

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING INCIDENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT)

6.1.2 RISING AWARENESS CAMPAIGNS AND PATIENT EDUCATION

6.1.3 ADVANCEMENTS IN TREATMENT OPTIONS FOR GRAFT-VERSUS-HOST DISEASE (GVHD)

6.2 RESTRAINTS

6.2.1 HIGH COST OF MEDICATIONS AND SUPPORTIVE CARE

6.2.2 DISEASE HETEROGENEITY IN GRAFT-VERSUS-HOST DISEASE (GVHD) IMPLICATIONS FOR TREATMENT AND CLINICAL TRIALS

6.3 OPPORTUNITIES

6.3.1 MARKET EXPANSION THROUGH STRATEGIC INITIATIVES AND PARTNERSHIP

6.3.2 GROWING PIPELINE OF INNOVATIVE DRUGS FOR GVHD TREATMENT

6.3.3 EMPOWERING PATIENT-CENTRIC APPROACH TO GVHD TREATMENT

6.4 CHALLENGES

6.4.1 STRINGENT REGULATIONS IN GVHD THERAPIES

6.4.2 SAFETY CONCERN AND COMPLEXITIES DURING TREATMENT

7 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET, BY TYPE

7.1 OVERVIEW

7.2 CHRONIC GVHD

7.2.1 CORTICOSTEROIDS

7.2.1.1 PREDNISOLONE

7.2.1.2 METHYLPREDNISOLONE

7.2.2 IMMUNOSUPPRESSIVE

7.2.2.1 MYCOPHENOLATE MOFETIL (MMF)

7.2.2.2 METHOTREXATE (MTX)

7.2.2.3 ANTITHYMOCYTE GLOBULIN (ATG)

7.2.2.4 OTHERS

7.2.3 CALCINEURIN INHIBITORS

7.2.4 OTHERS

7.2.5 BRANDED

7.2.5.1 REZUROCK

7.2.5.2 IMBRUVICA

7.2.5.3 JAKAFI

7.2.6 GENERIC

7.3 ACUTE GVHD

7.3.1 CORTICOSTEROIDS

7.3.1.1 METHYLPREDNISOLONE

7.3.1.2 PREDNISOLONE

7.3.2 IMMUNOSUPPRESSIVE

7.3.2.1 MYCOPHENOLATE MOFETIL (MMF)

7.3.2.2 RUXOLITINIB

7.3.2.3 OTHERS

7.3.3 CALCINEURIN INHIBITORS

7.3.3.1 TACROLIMUS (TAC)

7.3.3.2 CYCLOSPORIN (CSA)

7.3.4 OTHERS

7.4 PROPHYLACTIC

7.4.1 CYCLOSPORIN (CSA)

7.4.2 METHOTREXATE (MTX)

7.4.3 TACROLIMUS (TAC)

7.4.4 METHYLPREDNISOLONE

7.4.5 OTHERS

7.4.6 GENERIC

7.4.7 BRANDED

8 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY AGE

8.1 OVERVIEW

8.2 ADULTS

8.3 PEDIATRIC

9 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY GENDER

9.1 OVERVIEW

9.2 FEMALE

9.3 MALE

10 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION

10.1 OVERVIEW

10.2 ORAL

10.3 INTRAVENOUS

10.4 TOPICAL

10.5 OTHERS

11 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 CORTICOSTEROIDS

11.2.1.1 METHYLPREDNISOLONE

11.2.1.2 PREDNISOLONE

11.2.2 IMMUNOSUPPRESSIVE

11.2.2.1 MYCOPHENOLATE MOFETIL (MMF)

11.2.2.2 METHOTREXATE (MTX)

11.2.2.3 ANTITHYMOCYTE GLOBULIN (ATG)

11.2.2.4 OTHERS

11.2.3 CALCINEURIN INHIBITORS

11.2.3.1 TACROLIMUS (TAC)

11.2.3.2 CYCLOSPORIN (CSA)

11.2.3.3 OTHERS

11.2.4 BRANDED

11.2.4.1 REZUROCK

11.2.4.2 IMBRUVICA

11.2.4.3 JAKAFI

11.2.4.4 ORENCIA

11.2.4.5 OTHERS

11.2.5 GENERIC

11.3 THERAPY

12 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.2.1 PUBLIC

12.2.2 PRIVATE

12.3 TRANSPLANT CENTERS

12.4 INSTITUTES

12.5 SPECIALITY CENTERS

13 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAIL SALES

13.3.1 HOSPITAL PHARMACY

13.3.2 RETAIL PHARMACY

13.3.3 ONLINE PHARMACY

13.4 OTHERS

14 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION

14.1 OVERVIEW

14.2 NORTH AMERICA

14.2.1 U.S.

14.2.2 CANADA

14.2.3 MEXICO

14.3 EUROPE

14.3.1 GERMANY

14.3.2 FRANCE

14.3.3 ITALY

14.3.4 U.K.

14.3.5 SPAIN

14.3.6 BELGIUM

14.3.7 RUSSIA

14.3.8 SWITZERLAND

14.3.9 DENMARK

14.3.10 REST OF EUROPE

14.4 ASIA-PACIFIC

14.4.1 JAPAN

14.4.2 CHINA

14.4.3 AUSTRALIA

14.4.4 SOUTH KOREA

14.4.5 INDIA

14.4.6 MALAYSIA

14.4.7 SINGAPORE

14.4.8 PHILIPPINES

14.4.9 INDONESIA

14.4.10 REST OF ASIA-PACIFIC

14.5 SOUTH AMERICA

14.5.1 BRAZIL

14.5.2 ARGENTINA

14.5.3 REST OF SOUTH AMERICA

14.6 MIDDLE EAST AND AFRICA

14.6.1 SOUTH AFRICA

14.6.2 SAUDI ARABIA

14.6.3 U.A.E.

14.6.4 KUWAIT

14.6.5 BAHRAIN

14.6.6 REST OF MIDDLE EAST AND AFRICA

15 GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: GLOBAL

15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

15.3 COMPANY SHARE ANALYSIS: EUROPE

15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 BRISTOL-MYERS SQUIBB COMPANY

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENTS

17.2 ABBVIE INC.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENTS

17.3 JANSSEN GLOBAL SERVICES, LLC

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENTS

17.4 SANOFI

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENTS/NEWS

17.5 INCYTE

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENTS

17.6 ALKEM LABORATORIES LTD.

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.7 ASTELLAS PHARMA INC.

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 MALLINCKRODT

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENTS/NEWS

17.9 NOVARTIS AG

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PRODUCT PORTFOLIO

17.9.4 RECENT DEVELOPMENTS

18 QUESTIONNAIRE

19 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 2 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 3 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 4 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 5 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 6 GLOBAL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 7 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 9 GLOBAL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 10 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 11 GLOBAL IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 12 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 13 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 14 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 15 GLOBAL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 16 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 17 GLOBAL ADULTS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 18 GLOBAL PEDIATRIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 19 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 20 GLOBAL FEMALE IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 20218-2032 (USD THOUSAND)

TABLE 21 GLOBAL MALE IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 22 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 23 GLOBAL ORAL IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 24 GLOBAL INTRAVENOUS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 25 GLOBAL TOPICAL IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 26 GLOBAL OTHERS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 27 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 28 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 30 GLOBAL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 31 GLOBAL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 32 GLOBAL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 33 GLOBAL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 GLOBAL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 GLOBAL THERAPY IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 37 GLOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 GLOBAL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 39 GLOBAL TRANSPLANT CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 40 GLOBAL INSTITUTES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 41 GLOBAL SPECIALTY CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 42 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 43 GLOBAL DIRECT TENDER IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 44 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 GLOBAL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 46 GLOBAL OTHERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 47 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 48 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 49 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 50 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 51 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 52 NORTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 53 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 54 NORTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 55 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 57 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 58 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 59 NORTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 60 NORTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 61 NORTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 NORTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 63 NORTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 64 NORTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 65 NORTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 66 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 67 NORTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 69 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 70 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 71 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 72 NORTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 73 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 74 NORTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 75 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 76 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 77 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 78 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 79 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 80 U.S. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 81 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 83 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 84 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 85 U.S. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 86 U.S. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 88 U.S. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 89 U.S. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 90 U.S. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 91 U.S. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 92 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 93 U.S. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 94 U.S. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 95 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 96 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 97 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 98 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 99 U.S. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 100 U.S. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 101 U.S. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 102 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 103 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 104 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 105 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 106 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 107 CANADA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 108 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 111 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 112 CANADA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 113 CANADA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 CANADA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 116 CANADA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 117 CANADA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 118 CANADA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 119 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 120 CANADA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 CANADA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 123 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 124 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 125 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 126 CANADA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 127 CANADA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 128 CANADA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 129 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 130 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 131 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 132 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 133 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 134 MEXICO MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 138 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 139 MEXICO IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 140 MEXICO CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 MEXICO BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 MEXICO ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 143 MEXICO CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 144 MEXICO IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 145 MEXICO CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 146 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 147 MEXICO PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 149 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 150 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 151 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 152 MEXICO HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 153 MEXICO GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 154 MEXICO RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 155 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 156 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 157 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 158 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 159 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 160 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 161 EUROPE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 165 METHYLPREDNISOLONE

TABLE 166 EUROPE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 167 EUROPE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 EUROPE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 EUROPE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 170 EUROPE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 171 EUROPE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 172 EUROPE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 173 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 174 EUROPE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 176 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 177 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 178 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 179 EUROPE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 180 EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 181 EUROPE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 182 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 183 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 184 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 185 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 186 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 187 GERMANY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 189 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 191 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 192 GERMANY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 193 GERMANY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 GERMANY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 GERMANY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 196 GERMANY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 197 GERMANY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 198 GERMANY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 199 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 200 GERMANY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 202 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 203 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 204 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 205 GERMANY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 206 GERMANY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 207 GERMANY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 208 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 209 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 210 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 211 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 212 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 213 FRANCE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 214 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 217 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 218 FRANCE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 219 FRANCE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 FRANCE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 FRANCE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 222 FRANCE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 223 FRANCE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 224 FRANCE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 225 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 226 FRANCE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 228 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 229 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 230 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 231 FRANCE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 232 FRANCE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 233 FRANCE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 234 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 235 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 236 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 237 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 238 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 239 ITALY MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 241 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 242 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 243 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 244 ITALY IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 245 ITALY CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 ITALY BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 247 ITALY ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 248 ITALY CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 249 ITALY IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 250 ITALY CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 251 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 252 ITALY PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 253 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 254 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 255 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 256 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 257 ITALY HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 258 ITALY GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 259 ITALY RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 260 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 261 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 262 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 263 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 264 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 265 U.K. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 268 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 269 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 270 U.K. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 271 U.K. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 U.K. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 U.K. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 274 U.K. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 275 U.K. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 276 U.K. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 277 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 278 U.K. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 280 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 281 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 282 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 283 U.K. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 284 U.K. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 285 U.K. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 286 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 287 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 288 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 289 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 290 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 291 SPAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 292 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 294 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 295 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 296 SPAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 297 SPAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 SPAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 SPAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 300 SPAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 301 SPAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 302 SPAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 303 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 304 SPAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 306 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 307 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 308 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 309 SPAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 310 SPAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 311 SPAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 312 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 313 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 314 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 315 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 316 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 317 BELGIUM MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 318 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 321 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 322 BELGIUM IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 323 BELGIUM CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 BELGIUM BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 BELGIUM ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 326 BELGIUM CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 327 BELGIUM IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 328 BELGIUM CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 329 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 330 BELGIUM PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 332 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 333 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 334 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 335 BELGIUM HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 336 BELGIUM GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 337 BELGIUM RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 338 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 339 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 340 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 341 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 342 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 343 RUSSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 344 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 345 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 347 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 348 RUSSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 349 RUSSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 RUSSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 RUSSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 352 RUSSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 353 RUSSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 354 RUSSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 355 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 356 RUSSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 358 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 359 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 360 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 361 RUSSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 362 RUSSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 363 RUSSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 364 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 365 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 366 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 367 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 368 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 369 SWITZERLAND MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 371 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 373 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 374 SWITZERLAND IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 375 SWITZERLAND CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 SWITZERLAND BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 377 SWITZERLAND ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 378 SWITZERLAND CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 379 SWITZERLAND IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 380 SWITZERLAND CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 381 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 382 SWITZERLAND PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 383 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 384 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 385 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 386 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 387 SWITZERLAND HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 388 SWITZERLAND GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 389 SWITZERLAND RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 390 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 391 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 392 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 393 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 394 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 395 DENMARK MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 398 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 399 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 400 DENMARK IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 401 DENMARK CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 DENMARK BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 403 DENMARK ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 404 DENMARK CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 405 DENMARK IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 406 DENMARK CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 407 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 408 DENMARK PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 410 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 411 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 412 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 413 DENMARK HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 414 DENMARK GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 415 DENMARK RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 416 REST OF EUROPE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 417 ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 418 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 419 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 420 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 421 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 422 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 423 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 424 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 427 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 428 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 429 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 430 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 431 ASIA-PACIFIC ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 432 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 433 ASIA-PACIFIC IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 434 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 435 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 436 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 438 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 439 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 440 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 441 ASIA-PACIFIC HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 442 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 443 ASIA-PACIFIC RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 444 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 445 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 446 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 447 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 448 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 449 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 453 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 454 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 455 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 456 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 JAPAN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 458 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 459 JAPAN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 460 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 461 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 462 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 463 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 464 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 465 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 466 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 467 JAPAN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 468 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 469 JAPAN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 470 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 471 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 472 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 473 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 474 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 475 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 477 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 478 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 479 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 480 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 481 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 483 CHINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 484 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 485 CHINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 486 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 487 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 488 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 489 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 490 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 491 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 492 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 493 CHINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 494 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 495 CHINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 496 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 497 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 498 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 499 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 500 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 501 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 502 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 503 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 504 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 505 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 506 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 507 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 508 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 509 AUSTRALIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 510 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 511 AUSTRALIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 512 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 513 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 514 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 515 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 516 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 517 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 518 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 519 AUSTRALIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 520 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 521 AUSTRALIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 522 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 523 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 524 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 525 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 526 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 527 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 528 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 529 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 530 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 531 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 532 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 533 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 534 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 535 SOUTH KOREA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 536 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 537 SOUTH KOREA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 538 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 539 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 540 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 541 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 542 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 543 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 544 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 545 SOUTH KOREA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 546 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 547 SOUTH KOREA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 548 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 549 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 550 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 551 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 552 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 553 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 554 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 555 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 556 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 557 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 558 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 559 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 560 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 561 INDIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 562 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 563 INDIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 564 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 565 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 566 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 567 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 568 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 569 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 570 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 571 INDIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 572 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 573 INDIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 574 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 575 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 576 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 577 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 578 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 579 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 580 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 581 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 582 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 583 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 584 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 585 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 586 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 587 MALAYSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 588 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 589 MALAYSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 590 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 591 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 592 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 593 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 594 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 595 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 596 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 597 MALAYSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 598 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 599 MALAYSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 600 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 601 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 602 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 603 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 604 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 605 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 606 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 607 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 608 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 609 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 610 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 611 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 612 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 613 SINGAPORE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 614 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 615 SINGAPORE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 616 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 617 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 618 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 619 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 620 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 621 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 622 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 623 SINGAPORE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 624 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 625 SINGAPORE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 626 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 627 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 628 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 629 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 630 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 631 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 632 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 633 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 634 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 635 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 636 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 637 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 638 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 639 PHILIPPINES ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 640 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 641 PHILIPPINES IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 642 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 643 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 644 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 645 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 646 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 647 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 648 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 649 PHILIPPINES HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 650 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 651 PHILIPPINES RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 652 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 653 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 654 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 655 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 656 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 657 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 658 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 659 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 660 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 661 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 662 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 663 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 664 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 665 INDONESIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 666 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 667 INDONESIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 668 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 669 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 670 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 671 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 672 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 673 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 674 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 675 INDONESIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 676 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 677 INDONESIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 678 REST OF ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 679 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 680 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 681 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 682 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 683 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 684 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 685 SOUTH AMERICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 686 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 687 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 688 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 689 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 690 SOUTH AMERICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 691 SOUTH AMERICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 692 SOUTH AMERICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 693 SOUTH AMERICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 694 SOUTH AMERICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 695 SOUTH AMERICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 696 SOUTH AMERICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 697 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 698 SOUTH AMERICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 699 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 700 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 701 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 702 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 703 SOUTH AMERICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 704 SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 705 SOUTH AMERICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 706 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 707 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 708 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 709 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 710 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 711 BRAZIL MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 712 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 713 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 714 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 715 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 716 BRAZIL IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 717 BRAZIL CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 718 BRAZIL BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 719 BRAZIL ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 720 BRAZIL CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 721 BRAZIL IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 722 BRAZIL CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 723 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 724 BRAZIL PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 725 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 726 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 727 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 728 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 729 BRAZIL HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 730 BRAZIL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 731 BRAZIL RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 732 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 733 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 734 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 735 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 736 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 737 ARGENTINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 738 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 739 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 740 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 741 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 742 ARGENTINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 743 ARGENTINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 744 ARGENTINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 745 ARGENTINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 746 ARGENTINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 747 ARGENTINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 748 ARGENTINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 749 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 750 ARGENTINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 751 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 752 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 753 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 754 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 755 ARGENTINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 756 ARGENTINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 757 ARGENTINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 758 REST OF SOUTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 759 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 760 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 761 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 762 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 763 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 764 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 765 MIDDLE EAST AND AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 766 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 767 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 768 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 769 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 770 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 771 MIDDLE EAST AND AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 772 MIDDLE EAST AND AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 773 MIDDLE EAST AND AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 774 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 775 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 776 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 777 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 778 MIDDLE EAST AND AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 779 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 780 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 781 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 782 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 783 MIDDLE EAST AND AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 784 MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 785 MIDDLE EAST AND AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 786 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 787 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 788 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 789 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 790 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 791 SOUTH AFRICA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 792 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 793 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 794 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 795 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 796 SOUTH AFRICA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 797 SOUTH AFRICA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 798 SOUTH AFRICA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 799 SOUTH AFRICA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 800 SOUTH AFRICA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 801 SOUTH AFRICA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 802 SOUTH AFRICA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 803 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 804 SOUTH AFRICA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 805 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 806 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 807 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 808 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 809 SOUTH AFRICA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 810 SOUTH AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 811 SOUTH AFRICA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 812 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 813 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 814 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 815 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 816 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 817 SAUDI ARABIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 818 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 819 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 820 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 821 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 822 SAUDI ARABIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 823 SAUDI ARABIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 824 SAUDI ARABIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 825 SAUDI ARABIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 826 SAUDI ARABIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 827 SAUDI ARABIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 828 SAUDI ARABIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 829 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 830 SAUDI ARABIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 831 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 832 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 833 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 834 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 835 SAUDI ARABIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 836 SAUDI ARABIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 837 SAUDI ARABIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 838 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 839 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 840 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 841 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 842 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 843 U.A.E. MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 844 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 845 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 846 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 847 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 848 U.A.E. IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 849 U.A.E. CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 850 U.A.E. BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 851 U.A.E. ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 852 U.A.E. CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 853 U.A.E. IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 854 U.A.E. CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 855 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 856 U.A.E. PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 857 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 858 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 859 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 860 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 861 U.A.E. HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 862 U.A.E. GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 863 U.A.E. RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 864 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 865 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 866 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 867 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 868 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 869 KUWAIT MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 870 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 871 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 872 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 873 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 874 KUWAIT IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 875 KUWAIT CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 876 KUWAIT BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 877 KUWAIT ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 878 KUWAIT CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 879 KUWAIT IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 880 KUWAIT CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 881 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 882 KUWAIT PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 883 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 884 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 885 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 886 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 887 KUWAIT HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 888 KUWAIT GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 889 KUWAIT RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 890 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

TABLE 891 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 892 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 893 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 894 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 895 BAHRAIN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 896 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 897 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 898 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 899 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 900 BAHRAIN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 901 BAHRAIN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 902 BAHRAIN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 903 BAHRAIN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 904 BAHRAIN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 905 BAHRAIN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 906 BAHRAIN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 907 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)

TABLE 908 BAHRAIN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)

TABLE 909 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)

TABLE 910 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)

TABLE 911 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 912 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 913 BAHRAIN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 914 BAHRAIN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 915 BAHRAIN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 916 REST OF MIDDLE EAST AND AFRICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)

Abbildungsverzeichnis

FIGURE 1 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SEGMENTATION

FIGURE 11 THE GROWING NUMBER OF STEM CELL TRANSPLANTATIONS IS DRIVING THE GROWTH OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET FROM 2025 TO 2032

FIGURE 12 THE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET IN 2025 AND 2032

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING REGION FOR GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 15 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: EXECUTIVE SUMMARY

FIGURE 16 STRATEGIC DECISIONS

FIGURE 17 TWO SEGMENTS COMPRISE THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT

FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET

FIGURE 19 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, 2024

FIGURE 20 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, 2025-2032 (USD THOUSAND)

FIGURE 21 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, CAGR (2025-2032)

FIGURE 22 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, 2024

FIGURE 24 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, 2025-2032 (USD THOUSAND)

FIGURE 25 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, CAGR (2025-2032)

FIGURE 26 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, LIFELINE CURVE

FIGURE 27 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, 2024

FIGURE 28 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)

FIGURE 29 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, CAGR (2025-2032)

FIGURE 30 GLOBAL GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 31 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, 2024

FIGURE 32 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, 2025-2032 (USD THOUSAND)

FIGURE 33 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, CAGR (2025-2032)

FIGURE 34 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, 2024

FIGURE 36 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)

FIGURE 37 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)

FIGURE 38 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 39 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY END USER 2024

FIGURE 40 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 41 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: END USER, CAGR (2025-2032)

FIGURE 42 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: END USER, LIFELINE CURVE

FIGURE 43 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 44 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 45 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 46 GLOBAL GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 GLOBAL GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 48 GLOBAL GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)

FIGURE 49 NORTH AMERICA GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)

FIGURE 50 EUROPE GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)

FIGURE 51 AISA-PACIFIC GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)

Detaillierte Informationen anzeigen

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

Welche Hauptsegmente werden im Global Graft-Versus-Host Disease (GvHD) Treatment Market-Bericht behandelt?

Der Markt ist basierend auf Global Graft-Versus-Host Disease (GvHD) Treatment Market, By Treatment (Medication and Therapy), Type (Chronic GvHD, Acute GvHD, and Prophylactic), Gender (Female and Male), Age (Adults and Pediatric), Method of Administration (Oral, Intravenous, Topical, and Others), End User (Hospitals, Transplant Centers, Institutes and Specialty Centers), Distribution Channel (Direct Tender, Retail Sales and Others) - Industry Trends and Forecast to 2031. segmentiert.

Wie groß ist der aktuelle Markt für Global Graft-Versus-Host Disease (GvHD) Treatment Market?

Die Größe des Global Graft-Versus-Host Disease (GvHD) Treatment Market wurde im Jahr 2024 auf 4.07 USD Billion USD geschätzt.

Wie hoch ist die erwartete Wachstumsrate von Global Graft-Versus-Host Disease (GvHD) Treatment Market?

Der Global Graft-Versus-Host Disease (GvHD) Treatment Market wird voraussichtlich mit einer CAGR von 4.7% im Prognosezeitraum 2025 bis 2032 wachsen.

Wer sind die Hauptakteure im Global Graft-Versus-Host Disease (GvHD) Treatment Market?

Die Hauptakteure auf dem Markt sind Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, Mallinckrodt, Incyte, Sanofi, Alkem Laboratories Ltd..

Welche Länder werden im Global Graft-Versus-Host Disease (GvHD) Treatment Market-Bericht analysiert?

Der Marktbericht deckt Daten aus U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Belgium, Russia, Switzerland, Denmark, Rest of Europe, China, Japan, Australia, South Korea, India, Malaysia, Singapore, Philippines, Indonesia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Kuwait, Bahrain, and Rest of Middle East and Africa  ab.

Global Graft-Versus-Host Disease (GvHD) Treatment Market – Industry Trends and Forecast to 2031

Umgehen Sie die Zollherausforderungen mit agiler Supply-Chain-Beratung

Global Graft Versus Host Disease Gvhd Treatment Market

CAGR : 4.70 %

Graft-Versus-Host Disease (GvHD) Treatment Market Analysis and Insights

Globale Marktdynamik für die Behandlung der Graft-versus-Host-Krankheit (GvHD)

Globaler Marktumfang zur Behandlung der Graft-versus-Host-Krankheit (GvHD)

Globale Marktanalyse/Einblicke zur Behandlung der Graft-versus-Host-Krankheit (GvHD)

Wettbewerbsumfeld und globale Behandlung der Graft-Versus-Host-Krankheit (GvHD) Marktanteilsanalyse

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Berichte

Markteinblicke

Unterstützung

Lösungen

Global Graft-Versus-Host Disease (GvHD) Treatment Market – Industry Trends and Forecast to 2031

Umgehen Sie die Zollherausforderungen mit agiler Supply-Chain-Beratung

Global Graft Versus Host Disease Gvhd Treatment Market

CAGR : 4.70 %

Graft-Versus-Host Disease (GvHD) Treatment Market Analysis and Insights

Globale Marktdynamik für die Behandlung der Graft-versus-Host-Krankheit (GvHD)

Globaler Marktumfang zur Behandlung der Graft-versus-Host-Krankheit (GvHD)

Globale Marktanalyse/Einblicke zur Behandlung der Graft-versus-Host-Krankheit (GvHD)

Wettbewerbsumfeld und globale Behandlung der Graft-Versus-Host-Krankheit (GvHD) Marktanteilsanalyse

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Verwandte Seiten durchsuchen